Bridging the Gap: In This Era of Cancer Immunotherapy(Cancer Etiology, Diagnosis and Treatments)

弥合差距:在这个时代的癌症免疫治疗

肿瘤学

原   价:
2223.75
售   价:
1779.00
优惠
平台大促 低至8折优惠
发货周期:国外库房发货,通常付款后3-5周到货!
作      者
出  版 社
出版时间
2021年08月11日
装      帧
精装
ISBN
9781536199000
复制
页      码
311
语      种
英文
综合评分
暂无评分
我 要 买
- +
库存 30 本
  • 图书详情
  • 目次
  • 买家须知
  • 书评(0)
  • 权威书评(0)
图书简介
Recognizing rare diseases’ impracticability of having extensive clinical trials necessary for regulatory approval, the US Orphan Drug Act appropriately facilitates the commercialization of "orphan drugs." However, even common cancers also have rather specific but uncommon clinical situations for which extensive clinical trials are hardly practicable. Moreover, although such very costly and extensive trials often depend on industry support, uncommon situations are unattractive. Eventually, many specific treatments for designated clinical oncology situations often lack regulatory approvals merely because of suboptimal trial data. Now, this EBM (evidence-based medicine) book by expert authors with first-hand clinical experience is about off-label but acceptable treatment options. The attempt is to patch up the low response rates and considerable adverse events of novel immunotherapy. Currently, without any such off-label treatments, some cancer patients may well be left out in the cold. Although off-label treatments lack regulatory approval, they are backed by EBM and have good safety profiles. It’s inappropriate to announce “nothing else can be done” merely because all approved options have already been exhausted. In expert hands, despite the “on compassionate grounds” proviso, the safety profiles of such off-label prescriptions may even compare favorably with orthodox chemotherapy given at top doses.
本书暂无推荐
本书暂无推荐
看了又看
  • 上一个
  • 下一个